High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma

G. Bianchi, R. A. Kyle, D. R. Larson, Thomas Elmer Witzig, Shaji K Kumar, Angela Dispenzieri, W. G. Morice, S Vincent Rajkumar

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Smoldering multiple myeloma (SMM) carries a 50% risk of progression to multiple myeloma (MM) or related malignancy within the first 5 years following diagnosis. The goal of this study was to determine if high levels of circulating plasma cells (PCs) are predictive of SMM transformation within the first 2-3 years from diagnosis. Ninety-one patients diagnosed with SMM at Mayo Clinic from January 1994 through January 2007, who had testing for circulating PCs using an immunofluorescent assay and adequate follow-up to ascertain disease progression, were studied. High level of circulating PCs was defined as absolute peripheral blood PCs >5 × 10 6/l and/or >5% PCs per 100 cytoplasmic immunoglobulin (Ig)-positive peripheral blood mononuclear cells. Patients with high circulating PCs (14 of 91 patients, 15%) were significantly more likely to progress to active disease within 2 years compared with patients without high circulating PCs, 71% versus 24%, respectively, P=0.001. Corresponding rates for progression within 3 years were 86% versus 34%, respectively, P<0.001. Overall survival (OS) after both SMM diagnosis and MM diagnosis was also significantly different. High levels of circulating PCs identify SMM patients with an elevated risk of progression within the first 2-3 years following diagnosis.

Original languageEnglish (US)
Pages (from-to)680-685
Number of pages6
JournalLeukemia
Volume27
Issue number3
DOIs
StatePublished - Mar 2013

Fingerprint

Plasma Cells
Multiple Myeloma
Blood Cells
Disease Progression
Immunoglobulins
Survival
Neoplasms

Keywords

  • circulating plasma cells
  • multiple myeloma
  • predictive factor
  • progression
  • smoldering multiple myeloma

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma. / Bianchi, G.; Kyle, R. A.; Larson, D. R.; Witzig, Thomas Elmer; Kumar, Shaji K; Dispenzieri, Angela; Morice, W. G.; Rajkumar, S Vincent.

In: Leukemia, Vol. 27, No. 3, 03.2013, p. 680-685.

Research output: Contribution to journalArticle

@article{c68815a745554abd8d6171a26158ea18,
title = "High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma",
abstract = "Smoldering multiple myeloma (SMM) carries a 50{\%} risk of progression to multiple myeloma (MM) or related malignancy within the first 5 years following diagnosis. The goal of this study was to determine if high levels of circulating plasma cells (PCs) are predictive of SMM transformation within the first 2-3 years from diagnosis. Ninety-one patients diagnosed with SMM at Mayo Clinic from January 1994 through January 2007, who had testing for circulating PCs using an immunofluorescent assay and adequate follow-up to ascertain disease progression, were studied. High level of circulating PCs was defined as absolute peripheral blood PCs >5 × 10 6/l and/or >5{\%} PCs per 100 cytoplasmic immunoglobulin (Ig)-positive peripheral blood mononuclear cells. Patients with high circulating PCs (14 of 91 patients, 15{\%}) were significantly more likely to progress to active disease within 2 years compared with patients without high circulating PCs, 71{\%} versus 24{\%}, respectively, P=0.001. Corresponding rates for progression within 3 years were 86{\%} versus 34{\%}, respectively, P<0.001. Overall survival (OS) after both SMM diagnosis and MM diagnosis was also significantly different. High levels of circulating PCs identify SMM patients with an elevated risk of progression within the first 2-3 years following diagnosis.",
keywords = "circulating plasma cells, multiple myeloma, predictive factor, progression, smoldering multiple myeloma",
author = "G. Bianchi and Kyle, {R. A.} and Larson, {D. R.} and Witzig, {Thomas Elmer} and Kumar, {Shaji K} and Angela Dispenzieri and Morice, {W. G.} and Rajkumar, {S Vincent}",
year = "2013",
month = "3",
doi = "10.1038/leu.2012.237",
language = "English (US)",
volume = "27",
pages = "680--685",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma

AU - Bianchi, G.

AU - Kyle, R. A.

AU - Larson, D. R.

AU - Witzig, Thomas Elmer

AU - Kumar, Shaji K

AU - Dispenzieri, Angela

AU - Morice, W. G.

AU - Rajkumar, S Vincent

PY - 2013/3

Y1 - 2013/3

N2 - Smoldering multiple myeloma (SMM) carries a 50% risk of progression to multiple myeloma (MM) or related malignancy within the first 5 years following diagnosis. The goal of this study was to determine if high levels of circulating plasma cells (PCs) are predictive of SMM transformation within the first 2-3 years from diagnosis. Ninety-one patients diagnosed with SMM at Mayo Clinic from January 1994 through January 2007, who had testing for circulating PCs using an immunofluorescent assay and adequate follow-up to ascertain disease progression, were studied. High level of circulating PCs was defined as absolute peripheral blood PCs >5 × 10 6/l and/or >5% PCs per 100 cytoplasmic immunoglobulin (Ig)-positive peripheral blood mononuclear cells. Patients with high circulating PCs (14 of 91 patients, 15%) were significantly more likely to progress to active disease within 2 years compared with patients without high circulating PCs, 71% versus 24%, respectively, P=0.001. Corresponding rates for progression within 3 years were 86% versus 34%, respectively, P<0.001. Overall survival (OS) after both SMM diagnosis and MM diagnosis was also significantly different. High levels of circulating PCs identify SMM patients with an elevated risk of progression within the first 2-3 years following diagnosis.

AB - Smoldering multiple myeloma (SMM) carries a 50% risk of progression to multiple myeloma (MM) or related malignancy within the first 5 years following diagnosis. The goal of this study was to determine if high levels of circulating plasma cells (PCs) are predictive of SMM transformation within the first 2-3 years from diagnosis. Ninety-one patients diagnosed with SMM at Mayo Clinic from January 1994 through January 2007, who had testing for circulating PCs using an immunofluorescent assay and adequate follow-up to ascertain disease progression, were studied. High level of circulating PCs was defined as absolute peripheral blood PCs >5 × 10 6/l and/or >5% PCs per 100 cytoplasmic immunoglobulin (Ig)-positive peripheral blood mononuclear cells. Patients with high circulating PCs (14 of 91 patients, 15%) were significantly more likely to progress to active disease within 2 years compared with patients without high circulating PCs, 71% versus 24%, respectively, P=0.001. Corresponding rates for progression within 3 years were 86% versus 34%, respectively, P<0.001. Overall survival (OS) after both SMM diagnosis and MM diagnosis was also significantly different. High levels of circulating PCs identify SMM patients with an elevated risk of progression within the first 2-3 years following diagnosis.

KW - circulating plasma cells

KW - multiple myeloma

KW - predictive factor

KW - progression

KW - smoldering multiple myeloma

UR - http://www.scopus.com/inward/record.url?scp=84875210623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875210623&partnerID=8YFLogxK

U2 - 10.1038/leu.2012.237

DO - 10.1038/leu.2012.237

M3 - Article

VL - 27

SP - 680

EP - 685

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 3

ER -